Cancer Treatment Today

Waldenstrom's (WM)is an uncommon lymphoproliferative disorder characterized primarily by bone marrow infiltration and IgM monoclonal gammopathy. It should be considered a distinct clinicopathological entity rather than a clinical syndrome secondary to IgM secretion. Waldenström macroglobulinemia is a clonal disorder of B lymphocytes. This condition is considered to be lymphoplasmacytic lymphoma as defined by the Revised European American Lymphoma

Waldenstrom's (WM) should be considered cancer since it is a  presentation of a lymphoma. WM is an uncommon lymphoproliferative disorder characterized primarily by bone marrow infiltration and IgM monoclonal gammopathy. It should be considered a distinct clinicopathological entity rather than a clinical syndrome secondary to IgM secretion. Waldenström macroglobulinemia is a clonal disorder of B lymphocytes. This condition is considered to be lymphoplasmacytic

Waldenström's macroglobulinemia (WM) is a CD20 expressing B-cell malignancy represented by the pathological diagnosis of IgM secreting lymphoplasmacytic lymphoma. Since 1999, there have been many reprts and several phase II studies of Rituxan in this disease. Major response rates of 30% have been reported in most studies with standard dose rituximab, i.e. 4 weekly infusions at 375 mg/m2/week. A recent guideline states: "Rituximab is active in the

Waldenström's macroglobulinemia (WM) is a CD20 expressing B-cell malignancy represented by the pathological diagnosis of IgM secreting lymphoplasmacytic lymphoma. Chen, et al. (2007) found bortezomib to be an active agent in Waldenstrom's macroglobulinemia but it was an uncontrolled phase II clinical trial in which untreated or previously treateds ymptomatic patients with Waldenstrom's macroglobulnemia (n = 27) received bortezomib on a 21-day cycle

Lymphoplasmacytic lymphomas are low grade Non-Hodgkin's lymphomas and contain small lymphocytes, plasmacytoid lymphocytes, variable numbers of transformed cells, and plasma cells. It is the nodal; equivalent of Waldenstrom's (WM) macroglobulinemia. The question that needs to be addressed in the medical appropriateness of allogeneic transplantation and the proposed conditioning regimens for a low grade lymphoma as well as the disease specific question.

The hypogammaglobinemia and impaired T-cell function associated with Waldesntrom's macroglobulinemia predispose patients to potentially serious infections. CLL is a similar condition to Wandenstrom's and is much more common. IVIG is well established for CLL. UNfortunately, it is not similarly establisehd for Waldesntrom's. IgA and IgG hypogammaglobulinemia is common in Waldenström’s macroglobulinemia and persists despite therapeutic intervention

Waldenström's macroglobulinemia (WM) is a CD20 expressing B-cell malignancy represented by the pathological diagnosis of IgM secreting lymphoplasmacytic lymphoma. Since 1999, there have been many reprts and several  phase II studies of Rituxan in this disease. Major response rates of 30% have been reported in most studies with standard dose rituximab, i.e. 4 weekly infusions at 375 mg/m2/week.  A recent guideline states: "Rituximab is active in